Octapharma, the pharmaceutical company from Lachen in the canton of Schwyz, is set to present the latest concepts in factor VIII therapy for the treatment of hemophilia A at the 16th Annual Meeting of the European Association for Haemophilia and Allied Disorder (EAHAD) at the beginning of February. According to a press release, three Swiss patients and their accompanying medical professionals will be presented during an online symposium at the conference, which takes place February 7-10, 2023, in Manchester in the UK. The focus here will be on treatment perspectives with the novel compound Nuwiq (simoctocog alfa), a fourth-generation recombinant factor VIII (rFVIII) protein. By bringing together the views of clinicians and patients, the event organizers are hoping to increase both therapy safety and patient compliance.
Factor VIII, also called antihemophilic globulin A, is a glycoprotein that acts as a coagulation factor in vertebrates. A factor VIII deficiency leads to the blood disorder hemophilia A.
Octapharma is a globally active company that manufactures human proteins from blood plasma. Headquartered in Lachen, the company employs more than 10,000 staff and operates in 118 countries around the world. ww